Consumers are warned not to use certain jars of Earth's Best Organic 2 Apple Peach Barley Wholesome Breakfast baby food, because of a risk of Clostridium botulinum contamination. The affected foods were sold in individual jars and in variety packs (containing four jars of the apple peach barley in the pack along with other types). This line of food is a part of the "2nd Vegetables, Fruits, and Blends" intended for infants six months and older. Distribution was through retail stores and the Earth's Best Web site. Consumers should not use and destroy any of this product, even if it does not look or smell spoiled.
Consumers are warned not to use certain jars of Earth's Best Organic 2 Apple Peach Barley Wholesome Breakfast baby food, because of a risk of Clostridium botulinum contamination. The affected foods were sold in individual jars and in variety packs (containing four jars of the apple peach barley in the pack along with other types). This line of food is a part of the "2nd Vegetables, Fruits, and Blends" intended for infants six months and older. Distribution was through retail stores and the Earth's Best Web site. Consumers should not use and destroy any of this product, even if it does not look or smell spoiled. See the chart below for additional information:
According to the FDA, botulism can causes illness within 18-36 hours of exposure. Initial indications of illness in infants are decreased frequency or absence of stools. Other symptoms include poor feeding, weak suck, lethargy, listlessness, weak cry, and decreased body tone. Older patients who may use the product as part of a special diet might experience symptoms such as blurred vision, dizziness, dry mouth, and progressive weakness from head to legs. Constipation and urinary retention are also common.
The Hain Celestial Group initiated the baby food recall on February 9. The recall is ongoing and production of the product has been suspended while the source of contamination is investigated.
FDA issues second CRL for dasiglucagon to treat hypoglycemia in congenital hyperinsulinism
Published: October 8th 2024 | Updated: October 8th 2024This decision marks the second time the FDA has issued a complete response letter (CRL) for dasiglucagon to treat hypoglycemia in patients 7 days and up with congenital hyperinsulinism.